The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Cancer Policy

Trump signs order to boost domestic pharma manufacturing

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Amid continued anticipation about tariffs on pharmaceuticals, President Trump has signed an executive order to prioritize the onshoring of prescription drug manufacturing as part of his “America First” agenda. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Table of Contents

YOU MAY BE INTERESTED IN

Cancer Policy

CMS proposed rule would implement electronic prior authorization requirements for covered drugs in federal health plans

The Centers for Medicare & Medicaid Services issued the 2026 CMS Interoperability Standards and Prior Authorization for Drugs proposed rule, which aims to shorten care delays and improve transparency within federal health insurance programs by establishing electronic prior authorization, or ePA, requirements for covered prescription drugs and expedite federal response deadlines to ensure patients receive life-critical medications without administrative delay.
By Jacquelyn Cobb
Cancer Policy

Federal judge orders temporary block on 340B drug rebate pilot program

A federal judge has blocked the Health Resources and Services Administration from rolling out a pilot program that would reimburse safety net hospitals that get a discount on drugs through the 340B program via a rebate, as opposed to the status quo of up-front savings. The preliminary injunction was issued on Dec. 29, just a few days before the program was slated to begin on Jan 1. 
By Sara Willa Ernst
Byline
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account